CL2018001056A1 - Vacuna contra el virus herpes simplex - Google Patents
Vacuna contra el virus herpes simplexInfo
- Publication number
- CL2018001056A1 CL2018001056A1 CL2018001056A CL2018001056A CL2018001056A1 CL 2018001056 A1 CL2018001056 A1 CL 2018001056A1 CL 2018001056 A CL2018001056 A CL 2018001056A CL 2018001056 A CL2018001056 A CL 2018001056A CL 2018001056 A1 CL2018001056 A1 CL 2018001056A1
- Authority
- CL
- Chile
- Prior art keywords
- herpes simplex
- simplex virus
- virus vaccine
- vaccines
- arn
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000700584 Simplexvirus Species 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA DESCRIPCIÓN SE RELACIONA CON VACUNAS DE ÁCIDO RIBONUCLEICO (ARN) DEL VIRUS DEL HERPES SIMPLE (VHS), ASÍ COMO A MÉTODOS PARA UTILIZAR LAS VACUNAS Y A COMPOSICIONES QUE COMPRENDEN LAS VACUNAS.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245031P | 2015-10-22 | 2015-10-22 | |
US201562245159P | 2015-10-22 | 2015-10-22 | |
US201562247576P | 2015-10-28 | 2015-10-28 | |
US201562248252P | 2015-10-29 | 2015-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018001056A1 true CL2018001056A1 (es) | 2018-10-19 |
Family
ID=58558127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018001056A CL2018001056A1 (es) | 2015-10-22 | 2018-04-20 | Vacuna contra el virus herpes simplex |
Country Status (19)
Country | Link |
---|---|
US (2) | US20180303929A1 (es) |
EP (1) | EP3365009A4 (es) |
JP (2) | JP2018536023A (es) |
KR (1) | KR20180096593A (es) |
CN (1) | CN108472355A (es) |
AU (2) | AU2016342049B2 (es) |
BR (1) | BR112018008090A2 (es) |
CA (1) | CA3002822A1 (es) |
CL (1) | CL2018001056A1 (es) |
CO (1) | CO2018005258A2 (es) |
EA (1) | EA201890999A1 (es) |
IL (1) | IL258833A (es) |
MA (1) | MA46024A (es) |
MX (1) | MX2018004918A (es) |
PE (1) | PE20181531A1 (es) |
PH (1) | PH12018500855A1 (es) |
SG (1) | SG11201803365RA (es) |
TN (1) | TN2018000155A1 (es) |
WO (1) | WO2017070623A1 (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3981437A1 (en) | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
ES2937963T3 (es) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Vacunas de enfermedad infecciosa |
WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
SI3718565T1 (sl) | 2015-10-22 | 2022-08-31 | Modernatx, Inc. | Cepiva za respiratorni virus |
EA201891001A1 (ru) | 2015-10-22 | 2018-11-30 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv) |
EP3364982A4 (en) | 2015-10-22 | 2019-04-17 | ModernaTX, Inc. | VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
WO2017201340A2 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding relaxin |
MX2019002904A (es) | 2016-09-14 | 2019-09-26 | Modernatx Inc | Composiciones de arn de alta pureza y métodos para su preparación. |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
EP3538146A4 (en) | 2016-11-11 | 2020-07-15 | ModernaTX, Inc. | INFLUENZA VACCINE |
EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES |
US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
US11752206B2 (en) * | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
EP3607074A4 (en) | 2017-04-05 | 2021-07-07 | Modernatx, Inc. | REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY |
EP3641810A4 (en) * | 2017-04-26 | 2021-08-18 | Modernatx, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
EP3615060A4 (en) * | 2017-04-26 | 2021-06-09 | Merck Sharp & Dohme Corp. | HSV ANTIGENIC PEPTIDES AND HSV PROTEIN VACCINES |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
EP3668520A4 (en) * | 2017-08-17 | 2021-05-12 | The Trustees Of The University Of Pennsylvania | MODIFIED RNA VACCINES CODING FOR HERPES SIMPLEX VIRUS GLYCOPROTEINS AND THEIR USES |
WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
US11866696B2 (en) | 2017-08-18 | 2024-01-09 | Modernatx, Inc. | Analytical HPLC methods |
CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
CN109701008B (zh) * | 2019-02-18 | 2022-06-21 | 山东兴瑞生物科技有限公司 | 针对单纯疱疹病毒的治疗性dc复合疫苗及其制备方法 |
CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
EP3999093A4 (en) * | 2019-07-19 | 2023-11-22 | Merck Sharp & Dohme LLC | ANTIGEN GLYCOPROTEIN E POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF |
JP2022542032A (ja) * | 2019-07-21 | 2022-09-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 治療用ウイルスワクチン |
WO2021197589A1 (en) * | 2020-03-31 | 2021-10-07 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination |
CN113521268A (zh) | 2020-04-22 | 2021-10-22 | 生物技术Rna制药有限公司 | 冠状病毒疫苗 |
CN115803333A (zh) | 2020-07-02 | 2023-03-14 | 生命技术公司 | 三核苷酸帽类似物、其制备和用途 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
US20240156951A1 (en) * | 2021-03-11 | 2024-05-16 | Redbiotec Ag | Vaccine compositions and methods for treating hsv |
IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023107999A2 (en) | 2021-12-08 | 2023-06-15 | Modernatx, Inc. | Herpes simplex virus mrna vaccines |
WO2023147090A1 (en) * | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
US20240156949A1 (en) | 2022-10-28 | 2024-05-16 | Glaxosmithkline Biologicals Sa | Nucleic Acid Based Vaccine |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
WO1993001301A1 (en) * | 1991-07-05 | 1993-01-21 | The Penn State Research Foundation | Mutant antiviral regulatory proteins |
GB9406498D0 (en) * | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
US7094767B2 (en) * | 1994-07-22 | 2006-08-22 | Merck & Co., Inc. | Polynucleotide herpes virus vaccine |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
CA2270282A1 (en) * | 1996-11-04 | 1998-05-14 | Smithkline Beecham Corporation | Novel coding sequences from herpes simplex virus type-2 |
DE60031874D1 (de) * | 1999-09-30 | 2006-12-28 | Univ Washington | Immunologisch relevante antigene aus herpes simplexvirus |
AU7542301A (en) * | 2000-06-09 | 2001-12-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes<sup>TM</sup>) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
CA2830887C (en) | 2001-06-05 | 2016-11-29 | Curevac Gmbh | Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions |
AU2002319668A1 (en) | 2001-07-27 | 2003-02-17 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
AU2002332020A1 (en) | 2001-10-03 | 2003-04-14 | The Johns Hopkins University | Compositions for oral gene therapy and methods of using same |
WO2003092665A2 (en) | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
JP2007512355A (ja) * | 2003-11-21 | 2007-05-17 | アルザ コーポレイション | 開裂性のpegで表面修飾されたリポソーム−dna複合体で媒介される遺伝子送達 |
US8957034B2 (en) | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
NZ550320A (en) | 2004-04-15 | 2010-02-26 | Chiasma Inc | Compositions capable of facilitating penetration across a biological barrier |
EP1856179B1 (en) | 2004-12-10 | 2013-05-15 | Kala Pharmaceuticals, Inc. | Functionalized poly (ether-anhydride) block copolymers |
KR101288729B1 (ko) | 2005-04-01 | 2013-07-23 | 인터자인 테크놀로지스, 인코포레이티드 | 약물 전달용 중합체성 마이셀 |
US8273339B2 (en) | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
EP1896082B1 (en) | 2005-06-16 | 2012-12-26 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
US9149543B2 (en) * | 2005-12-15 | 2015-10-06 | The Trustees Of The University Of Pennsylvania | Methods and models for rapid, widespread delivery of genetic material to the CNS using non-viral, cationic lipid-mediated vectors |
US8309680B2 (en) | 2006-02-21 | 2012-11-13 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
WO2007133807A2 (en) | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
AU2007252296A1 (en) * | 2006-05-19 | 2007-11-29 | The Walter And Eliza Hall Institute Of Medical Research | Immunogenic compositions |
WO2008011609A2 (en) * | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
JP2010502713A (ja) | 2006-09-08 | 2010-01-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 粘液を通る輸送を増強するための組成物および方法 |
EP2120859B1 (en) | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
US8877206B2 (en) * | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
PT2136788E (pt) | 2007-03-30 | 2012-02-03 | Bind Biosciences Inc | Direccionamento a células de cancro utilizando nanopartículas |
WO2010005721A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
JP2012501966A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法 |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
ES2654533T3 (es) | 2008-06-16 | 2018-02-14 | Pfizer Inc. | Procedimientos para la preparación de copolímeros dibloque funcionalizados con un agente de direccionamiento para su uso en la fabricación de nanopartículas terapéuticas |
US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
JP5823405B2 (ja) | 2009-11-04 | 2015-11-25 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 核酸含有脂質粒子および関連方法 |
EA201290498A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения |
EP2512487A4 (en) | 2009-12-15 | 2013-08-07 | THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
JP5965844B2 (ja) | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物 |
JP5988435B2 (ja) | 2010-01-24 | 2016-09-07 | ノバルティス アーゲー | 放射線照射された生分解性微粒子 |
US9089537B2 (en) * | 2010-02-26 | 2015-07-28 | The Trustees Of The University Of Pennslyvania | Subunit vaccines for herpes viruses and methods of use |
US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
US20130196948A1 (en) | 2010-06-25 | 2013-08-01 | Massachusetts Insitute Of Technology | Polymers for biomaterials and therapeutics |
WO2012006376A2 (en) * | 2010-07-06 | 2012-01-12 | Novartis Ag | Virion-like delivery particles for self-replicating rna molecules |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
KR102162111B1 (ko) * | 2010-10-11 | 2020-10-07 | 노파르티스 아게 | 항원 전달 플랫폼 |
JP2013543844A (ja) | 2010-10-22 | 2013-12-09 | バインド セラピューティックス インコーポレイテッド | 高分子コポリマーを含む治療用ナノ粒子 |
WO2012061703A1 (en) | 2010-11-05 | 2012-05-10 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
WO2012099805A2 (en) | 2011-01-19 | 2012-07-26 | Ocean Nanotech, Llc | Nanoparticle based immunological stimulation |
AU2012212264B2 (en) * | 2011-01-31 | 2016-01-28 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
AU2012237260A1 (en) | 2011-03-31 | 2013-11-14 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
CA2831471C (en) | 2011-03-31 | 2020-02-25 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
US20140308363A1 (en) | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
RU2014104090A (ru) * | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
ES2670944T3 (es) | 2011-07-21 | 2018-06-04 | Croda International Plc | Copolímeros de bloques de poliéter-poliamida ramificados y métodos de preparación y uso de los mismos |
US8932572B2 (en) | 2011-08-26 | 2015-01-13 | Arrowhead Madison Inc. | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
KR20140067070A (ko) | 2011-08-31 | 2014-06-03 | 말린크로트 엘엘씨 | H-포스포네이트에 의한 나노입자 peg 개질 |
EP2747761A1 (en) | 2011-09-22 | 2014-07-02 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
EP2768530A1 (en) * | 2011-10-11 | 2014-08-27 | Novartis AG | Recombinant self-replicating polycistronic rna molecules |
PL3597644T3 (pl) | 2011-10-18 | 2022-01-17 | Dicerna Pharmaceuticals, Inc. | Aminowe lipidy kationowe i ich zastosowania |
CN107522664B (zh) | 2011-10-27 | 2021-03-16 | 麻省理工学院 | 能够形成药物包封微球的在n末端上官能化的氨基酸衍生物 |
WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
EP2791160B1 (en) * | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
CN104936620B (zh) | 2012-01-19 | 2019-08-09 | 约翰霍普金斯大学 | 增强粘膜渗透的纳米粒子调配物 |
WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP2809702B1 (en) | 2012-02-03 | 2017-12-20 | Rutgers, The State University of New Jersey | Polymeric biomaterials derived from phenolic monomers and their medical uses |
WO2013120052A1 (en) | 2012-02-10 | 2013-08-15 | E. I. Du Pont De Nemours And Company | Preparation, purification and use of high-x diblock copolymers |
WO2013143555A1 (en) * | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
US20150307542A1 (en) * | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
US20150366997A1 (en) * | 2012-12-07 | 2015-12-24 | Shire Human Genetics Therapies, Inc. | COMPOSITIONS AND METHODS FOR mRNA DELIVERY |
EP3932947A1 (en) * | 2013-03-14 | 2022-01-05 | Translate Bio MA, Inc. | Methods and compositions for delivering mrna coded antibodies |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
US10590161B2 (en) | 2013-03-15 | 2020-03-17 | Modernatx, Inc. | Ion exchange purification of mRNA |
US10130649B2 (en) * | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
EP3981437A1 (en) * | 2014-04-23 | 2022-04-13 | ModernaTX, Inc. | Nucleic acid vaccines |
US20200172928A1 (en) * | 2017-06-05 | 2020-06-04 | The Brigham And Women's Hospital, Inc. | Vero cell lines stably expressing hsv icp0 protein |
-
2016
- 2016-10-21 WO PCT/US2016/058322 patent/WO2017070623A1/en active Application Filing
- 2016-10-21 JP JP2018541090A patent/JP2018536023A/ja active Pending
- 2016-10-21 US US15/767,618 patent/US20180303929A1/en not_active Abandoned
- 2016-10-21 MA MA046024A patent/MA46024A/fr unknown
- 2016-10-21 AU AU2016342049A patent/AU2016342049B2/en active Active
- 2016-10-21 CN CN201680075061.1A patent/CN108472355A/zh active Pending
- 2016-10-21 KR KR1020187014340A patent/KR20180096593A/ko unknown
- 2016-10-21 TN TNP/2018/000155A patent/TN2018000155A1/en unknown
- 2016-10-21 BR BR112018008090A patent/BR112018008090A2/pt not_active Application Discontinuation
- 2016-10-21 SG SG11201803365RA patent/SG11201803365RA/en unknown
- 2016-10-21 MX MX2018004918A patent/MX2018004918A/es unknown
- 2016-10-21 EP EP16858403.5A patent/EP3365009A4/en active Pending
- 2016-10-21 CA CA3002822A patent/CA3002822A1/en active Pending
- 2016-10-21 PE PE2018000600A patent/PE20181531A1/es unknown
- 2016-10-21 EA EA201890999A patent/EA201890999A1/ru unknown
-
2018
- 2018-04-20 CL CL2018001056A patent/CL2018001056A1/es unknown
- 2018-04-20 PH PH12018500855A patent/PH12018500855A1/en unknown
- 2018-04-22 IL IL258833A patent/IL258833A/en unknown
- 2018-05-21 CO CONC2018/0005258A patent/CO2018005258A2/es unknown
-
2021
- 2021-12-16 JP JP2021204272A patent/JP2022037134A/ja active Pending
-
2023
- 2023-08-17 AU AU2023216825A patent/AU2023216825A1/en active Pending
- 2023-10-04 US US18/481,204 patent/US20240173400A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20180096593A (ko) | 2018-08-29 |
CN108472355A (zh) | 2018-08-31 |
US20240173400A1 (en) | 2024-05-30 |
WO2017070623A1 (en) | 2017-04-27 |
PE20181531A1 (es) | 2018-09-26 |
CO2018005258A2 (es) | 2018-11-22 |
EP3365009A1 (en) | 2018-08-29 |
JP2022037134A (ja) | 2022-03-08 |
MA46024A (fr) | 2019-07-03 |
CA3002822A1 (en) | 2017-04-27 |
AU2023216825A1 (en) | 2023-09-07 |
IL258833A (en) | 2018-06-28 |
PH12018500855A1 (en) | 2018-10-29 |
EP3365009A4 (en) | 2019-07-03 |
MX2018004918A (es) | 2019-04-01 |
EA201890999A1 (ru) | 2018-12-28 |
JP2018536023A (ja) | 2018-12-06 |
TN2018000155A1 (en) | 2019-10-04 |
BR112018008090A2 (pt) | 2018-11-13 |
AU2016342049A1 (en) | 2018-06-07 |
AU2016342049B2 (en) | 2023-05-18 |
US20180303929A1 (en) | 2018-10-25 |
SG11201803365RA (en) | 2018-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001056A1 (es) | Vacuna contra el virus herpes simplex | |
CL2018001053A1 (es) | Vacuna contra el virus sincicial respiratorio | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
MD3718565T2 (ro) | Vaccinuri împotriva virusului respirator | |
CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
UY36766A (es) | Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen | |
BR112016024644A2 (pt) | vacinas de ácido nucleico | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
BR112017027132A2 (pt) | reguladores do nrf2 | |
CL2016003277A1 (es) | Métodos para preparar análogos de nucleótido sustituidos | |
BR112017027137A2 (pt) | reguladores de nrf2 | |
CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
CO2017002253A2 (es) | Compuesto dirigido a il-23a y tnf-alfa | |
MX2021010060A (es) | Produccion de virus en huevos aviares. | |
DOP2022000085A (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
BR112016018654A2 (pt) | Composições de silicato estabilizadas e seu uso como composições antiperspirantes | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
CO2018010359A2 (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
PE20160596A1 (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana | |
EA201991319A1 (ru) | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
TR201819130T4 (tr) | Sulu Formülasyonlar, Bunların Üretimi Ve Kullanımı | |
AR106464A1 (es) | Vacuna de virus sincitial respiratorio |